Loading…
CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus
BACKGROUND The aetiology of systemic lupus erythematosus (SLE) is still unknown. In several cases, however, chemicals or drugs were identified as aetiological agents and associations with certain phenotypes of drug metabolising enzymes have been reported. The purpose of this study was to discover if...
Saved in:
Published in: | Annals of the rheumatic diseases 1999-03, Vol.58 (3), p.182-185, Article 182 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | BACKGROUND The aetiology of systemic lupus erythematosus (SLE) is still unknown. In several cases, however, chemicals or drugs were identified as aetiological agents and associations with certain phenotypes of drug metabolising enzymes have been reported. The purpose of this study was to discover if there is an association between CYP2C19 polymorphism and susceptibility to SLE. METHODS Racemic mephenytoin (100 mg orally) was given to healthy volunteers (n=161) and SLE patients (n=37) and then S-mephenytoin and R-mephenytoin were determined in eight hour urine samples. A 10 ml blood sample was obtained from healthy volunteers (n=80) and SLE patients (n=69) for genotypic assay. Each blood sample was tested for the detection ofCYP2C19*1 andCYP2C19*2 (formerly wt and m1 respectively) by oligonucleotide ligation assay. RESULTS The ratio of S/R-mephenytoin ranged from |
---|---|
ISSN: | 0003-4967 1468-2060 |
DOI: | 10.1136/ard.58.3.182 |